Role of iron in the molecular pathogenesis of diseases and therapeutic opportunities

U Abbasi, S Abbina, A Gill, LE Takuechi… - ACS Chemical …, 2021 - ACS Publications
Iron is an essential mineral that serves as a prosthetic group for a variety of proteins involved
in vital cellular processes. The iron economy within humans is highly conserved in that there …

Thalassemia in Indonesia

PA Wahidiyat, TT Sari, LD Rahmartani, SD Iskandar… - …, 2022 - Taylor & Francis
Indonesia is located along the 'Thalassemia Belt'and a hotspot for hemoglobinopathies.
Around 3.0–10.0% of the population carry β-thalassemia (β-thal) and 2.6–11.0% of the …

Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia

R Mohamed, AH Abdul Rahman, F Masra… - Frontiers in …, 2022 - frontiersin.org
Study background Thalassemia is the commonest genetic blood disorder in Malaysia which
requires life-long blood transfusions. From a total of 7,984 thalassemia patients in Malaysia …

[HTML][HTML] Advances in iron chelation therapy: transitioning to a new oral formulation

NR Shah - Drugs in context, 2017 - ncbi.nlm.nih.gov
Iron overload is a concern for patients who require repeated red-blood-cell transfusions due
to conditions such as sickle cell disease, thalassemia, or myelodysplastic syndromes. The …

Successful deferasirox rechallenge and treating through reaction in a patient with challenge-proven mild immediate reaction: A case report

M Sompornrattanaphan, T Krikeerati… - Journal of Asthma …, 2020 - Taylor & Francis
This is the first report of successful deferasirox administration, using graded challenge and
treating through, in a patient with mild immediate hypersensitivity reaction. Beginning with …

Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male

J Fraser, R Brook, T He, D Lewis - BMJ Case Reports CP, 2020 - casereports.bmj.com
A 33-year-old male presenting with subacute abdominal pain was found to have
hyperbilirubinaemia, hypokalaemia and hyponatraemia. This was in the setting of …

[PDF][PDF] Deferasirox adherence in patients with thalassemia: Exploring the association with patient knowledge and ferritin levels

RA Shaker, FA Rizij, TA Jasim - Pharmacia, 2024 - pharmacia.pensoft.net
In this study, data from 171 patients with thalassemia were analyzed. There was high
variability in ferritin levels among patients, with a median of 2290 ng/mL. The median …

Prenatal Diagnosis of Beta-Thalassemia Disease and Fate of Fetuses Among Beta-Thalassemia Carrier Mothers: An Experience at Tertiary Care Hospital of Rahim …

MB Ghafoor, SM Khan, F Sarwar… - Medical Forum …, 2023 - medicalforummonthly.com
Objective: To assess the status of beta thalassemia disease in fetuses of beta thalassemia
carrier mothers and to determine the fate of these fetuses. Study Design: A cross sectional …

[PDF][PDF] Systemic therapy for the treatment of adult patients with lower-risk myelodysplastic syndromes

R Buckstein, F Baldassarre, D Maze, A Schuh… - 2018 - cancercareontario.ca
The MDS are clonal hematopoietic stem cell disorders characterized by ineffective
hematopoiesis, leading to peripheral blood cytopenias, red blood cell and platelet …

[PDF][PDF] New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or MDS: results of the randomized, phase II eclipse study

A Taher, R Origa, S Perrotta… - Pediatric Blood and …, 2017 - kategorizacia.mzsr.sk
Introduction Methods Results Conclusions References Acknowledgments Disclosure Statement
Page 1 New Film-Coated Tablet Formulation of Deferasirox is Well Tolerated in Patients With …